BiotechTube

febuxostat + Allopurinol

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gout

Conditions

Gout

Trial Timeline

Mar 1, 2011 → Feb 1, 2012

NCT ID
NCT01736514

About febuxostat + Allopurinol

febuxostat + Allopurinol is a phase 3 stage product being developed by Astellas Pharma for Gout. The current trial status is completed. This product is registered under clinical trial identifier NCT01736514. Target conditions include Gout.

What happened to similar drugs?

12 of 20 similar drugs in Gout were approved

Approved (12) Terminated (3) Active (7)
✅LumiracoxibNovartisApproved
✅Pegloticase + MethotrexateAmgenApproved
✅Pegloticase + Methotrexate (MTX)AmgenApproved
✅Pegloticase + Methotrexate (MTX) + Standard Gout Flare Prophylaxis + Infusion Reaction (IR) ProphylaxisAmgenApproved
✅Pegloticase + methotrexate + placebo + gout flare prophylaxis regimen + fexofenadine + acetaminophen + methylprednisoloneAmgenApproved
✅Etanercept + Triamcinolone AcetonideAmgenApproved
✅PegloticaseAmgenApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01736514Phase 3Completed

Competing Products

20 competing products in Gout

See all competitors
ProductCompanyStageHype Score
Dotinurad + FebuxostatEisaiPhase 3
40
BaricitinibEli LillyPhase 2
35
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 1
25
SHR4640 tablet + SHR4640 tablet + febuxostat tablet + SHR4640 placebo tabletJiangsu Hengrui MedicinePhase 2
31
repaglinide; midazolam; SHR4640 + repaglinide; midazolam; SHR4640; SHR4640 placebo + repaglinide; midazolam; SHR4640 placeboJiangsu Hengrui MedicinePhase 1
29
SHR4640 + placeboJiangsu Hengrui MedicinePhase 1
29
SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MGJiangsu Hengrui MedicinePhase 3
40
Colchicine + Febuxostat + SHR4640Jiangsu Hengrui MedicinePhase 1
29
SHR4640 + AllopurinolJiangsu Hengrui MedicinePhase 3
40
SHR4640 ；Febuxostat + SHR4640 ; Febuxostat + SHR4640 + SHR4640 + FebuxostatJiangsu Hengrui MedicinePhase 2
42
SHR4640Jiangsu Hengrui MedicinePhase 1
25
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
47
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
40
SHR4640 + PlaceboJiangsu Hengrui MedicinePhase 1
29
Zurampic® + Control group: xanthine oxidase inhibitor monotherapyAstraZenecaPre-clinical
18
Risk of selected safety eventsAstraZenecaPre-clinical
26
AZD6140 + Placebo to match AZD6140AstraZenecaPhase 1
29
RDEA3170 + Allopurinol + PlaceboAstraZenecaPhase 2
35
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
32
Canakinumab pre-filled syringe + Canakinumab lyophilized powder + Triamcinolone Acetonide + PlaceboNovartisPhase 3
40